BioSpace News Archive

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets.

Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported financial results for the third quarter of 2022 and highlighted recent achievements and developments.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the company will participate in the Sidoti Micro-Cap Virtual Conference, November 9 - 10, 2022.

EyePoint Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate developments.

Decibel Therapeutics announced the submission of Clinical Trial Applications to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom and the Spanish Agency of Medicines and Medical Devices for a Phase 1/2 clinical trial in pediatric patients of DB-OTO, a gene therapy product candidate designed to provide durable hearing in individuals with profound congenital hearing loss due to an otoferlin deficiency.

AIM ImmunoTech Inc. announced the U.S. Food and Drug Administration has granted Orphan Drug Designation to Ampligen® for the treatment of Ebola virus disease.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced that the Company will present at the upcoming Stifel 2022 Healthcare Conference.

Oryzon Genomics, S.A. reported financial results for the third quarter of 2022 and provided an update on recent developments.

Tiziana Life Sciences Ltd. announced completion of enrollment of the first patient cohort in its Intermediate-Size Patient Population Expanded Access Program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis patients has quickly been completed, following the start of enrollment announced last week.

Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the third quarter and first nine months of 2022.